

1

# **Study Data Standards Update for CBER:** Your Guide To A Successful Submission

### October 2022

#### Lisa Lin Gabriela Lopez Mitnik

Data Standards Branch, Office of Regulatory Operations, Center for Biologics Evaluation and Research, U.S. Food & Drug Administration

www.fda.gov

# **Overview**

- Non-Clinical Data:
  - CBER requirements for Standard for Exchange of Nonclinical Data (SEND) and Technical Rejection Criteria (TRC)
  - SEND data common issues
- Clinical Data:
  - CBER Study Data standards validation Process
  - Common data validation issues
- Resources



# Non-Clinical Data: CBER requirements for Standard for Exchange of Nonclinical Data (SEND) and Technical Rejection Criteria (TRC)

www.fda.gov

# "The Center For Biologics Evaluation And Research (CBER) FDA Intends To Receive SEND Datasets In Future Submissions."



Use	Data Exchange Standard	Supported Implementation Guide Version	FDA Center(s)	Date Support Begins (MM/DD/YYYY)	Date Support Ends (MM/DD/YYYY)	Date Requirement Begins (MM/DD/YYYY) [10] [11]
Animal study datasets	SEND	3.1	CDER	08/21/2017		03/15/2019 [1] 03/15/2020 [2]
Animal study datasets	SEND	3.1	CBER	03/15/2021		03/15/2023



#### WE ARE ON THE WAY! ASSESSING, ANALYZING, RECOMMENDING, PILOTING, IMPLEMENTING

<sup>1</sup> Jhttps://www.fda.gov/industry/fda-data-standards-advisory-board/study-data-standards-resources (July 2022) 4

www.fda.gov

#### Nonclinical studies that start after March 15, 2023 must be in SEND format for submission to CBER

<u>Federal Register</u> <u>Notice</u> was published in July 2020, announcing CBER's support and future requirement for SEND

#### PUBLISHED DOCUMENT

#### AGENCY:

Food and Drug Administration, HHS.

#### ACTION:

Notice.

#### SUMMARY:

The Food and Drug Administration (FDA or Agency) Center for Biologics Evaluation and Research (CBER) is announcing support for the current version of Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Nonclinical Data (SEND) and an update to the FDA Data Standards Catalog for the submission of nonclinical data in new drug applications (NDAs), abbreviated new drug applications (ANDAs), certain biologics license applications (BLAs), and certain investigational new drug applications (INDs). This update does not apply to noncommercial INDs for a product that is not intended for commercial distribution (research and investigator-sponsored INDs); INDs and BLAs for devices that are regulated by CBER as biological products under the Public Health Services (PHS) Act; and submissions for blood and blood components, including Source Plasma.

Start Printed Page 42412 ----

#### DOCUMENT DETAILS

Printed version:

Publication Date: 07/14/2020

Agencies: Food and Drug Administration

Document Type:

Notice

Document Citation: 85 FR 42411

Page: 42411-42412 (2 pages)

Agency/Docket Number: Docket No. FDA-2020-N-1313

2020-15095


#### DOCUMENT DETAILS

#### DOCUMENT STATISTICS

Page views: 927 as of 11/03/2020 at 12:15 pm EST

https://www.federalregister.gov/documents/2020/07/14/2020-15095/electronic-submissions-data-standards-support-for-standard-for-the-exchange-of-nonclinical-data

# **FDA Technical Rejection Criteria For Study Data**



# CBER WILL BEGIN VALIDATION ON MARCH 16, 2023.



# Non-Clinical Data: SEND data common issues

www.fda.gov www.fda.gov

# **SEND Data Exploration**





• Data standards group loads SEND data in SEND Explorer immediately after receiving the submission data




 Data standards group grants access to reviewers to SEND explorer



• Reviewers use SEND Explorer and JMP/JMP Clinical for visualization, query and data summarization

# **Body Weight Changes**






www.fda.gov

9

# **Temperature Levels**



www.fda.gov

# **Microscopic Findings-Table**



													_	-	_	_			_
LYMPH NODE, ILIAC	UNREMARKABLE				11	1   1	1	1 1	1 1	1	1 1	10							1 1
LYMPH NODE, ILIAC	Erythrocytosis	NON-NEOPLASTIC	1 OF 5		1							0						1	1
LYMPH NODE, ILIAC	Increased cellularity	NON-NEOPLASTIC	1 OF 5		2							0				1	1		2
LYMPH NODE, ILIAC	Increased cellularity	NON-NEOPLASTIC	2 OF 5		7							0	1 2	1	2 '	1		1 1	7
LYMPH NODE, ILIAC	Increased cellularity	NON-NEOPLASTIC	3 OF 5		2							0		1	-	1			2
			LYMPH NO	E, ILIAC Examined:	20	1 1	1	1 1	1 1	1	1 1	10	1 1	1	1 1	1 1	1	1 1	1 10
LYMPH NODE, MESENTERIC	UNREMARKABLE				18	1 1	1	1 1	1 1	1	1 1	10	1 1	1	1	1	1	1	1 8
LYMPH NODE, MESENTERIC				NOT DONE	2							0				1		1	2
		LYM	PH NODE, MESE	ENTERIC Examined:	18	1 1	1	1 1	1 1	1	1 1	10	1 1	1	1	1	1	1	1 8
SITE, APPLICATION	UNREMARKABLE				20	3 3	3	3 2	3 3	3	3 3	10	1 2	1	1 1	1 3	1:	3 3	2 10
SITE, APPLICATION	Cellular debris	NON-NEOPLASTIC	1 OF 5		1							0	1						1
SITE, APPLICATION	HEMORRHAGE	NON-NEOPLASTIC	1 OF 5		1							0	1						1
SITE, APPLICATION	HEMORRHAGE	NON-NEOPLASTIC	2 OF 5		2							0	1		1	2			2
SITE, APPLICATION	Infiltration, mixed cell	NON-NEOPLASTIC	1 OF 5		3							0	1	1	1				3
SITE, APPLICATION	Infiltration, mononuclear cell	NON-NEOPLASTIC	1 OF 5		5							0		1	1	1	2		1 5
SITE, APPLICATION	Inflammation, mixed cell	NON-NEOPLASTIC	2 OF 5		2							0			1	1			2
SITE, APPLICATION	Inflammation, mixed cell	NON-NEOPLASTIC	3 OF 5		2							0	1			1			2
SITE, APPLICATION	Inflammation, mononuclear cell	NON-NEOPLASTIC	1 OF 5		1			1				1							0
SITE, APPLICATION	Necrosis	NON-NEOPLASTIC	2 OF 5		1							0			1				1
SITE, APPLICATION	Necrosis	NON-NEOPLASTIC	3 OF 5		2							0	1			1			2
			SITE, APPL	ICATION Examined:	20	1 1	1	1 1	1 1	1	1 1	10	1 1	1	1	1 1	1	1 1	1 10
SPLEEN	UNREMARKABLE				11	1 1	1	1 1	1 1	1	1 1	10						1	1
SPLEEN	Increased cellularity	NON-NEOPLASTIC	1 OF 5		4							0			1	1 1	1		1 4
SPLEEN	Increased cellularity	NON-NEOPLASTIC	2 OF 5		5							0	1 1	1	1			1	5
				SPLEEN Examined:	20	1 1	1	1 1	1 1	1	1 1	10	1 1	1	1 1	1 1	1	1 1	1 10

# **SEND Data Loading Issues**



Upload Study Data	Next Scheduled Load: 2/1/21 12:00 AM

Presets V Save as Preset

44 4	1 of 6	Rows 108 of	3,413 🂙   Select Columns	Reset	Export V Study Dashboard					
Application ID	Study ID	Sponsor Reference ID	Treatment	Species T	Study Title	Study Type	Study Start Date	Domains	Last Loaded Date <b>v V</b>	Load T
IND 12345	OPQ	NOT APPLICABLE	TRPC-05	DOG	TBPC-05: 28-Day Oral Dose Toxicity and Toxicokinetic Study in Beagle Dogs with 28-Day Dose-free Recovery	REPEAT DOSE TOXICITY	1/23/19	BW, CL, DM, DS, EG, EX, FW, LB, MA, MI, OM, PC, PP, RELREC, SE, SUPPMA, SUPPMI, SUPPPC, TA, TE, TS, TX	6/10/22 11:27 AM	
IND 54321	ABCD	NOT APPLICABLE	7НР349 also called мртне-о9	RAT	MPTHE-09-28 DAY REPEAT DOSE ORAL GAVAGE TOXICTY AND TOXICONNETICS STUDY IN SPRAGUE DAWLEY RATS WITH 28-DAY RECOVERY PERIOD	REPEAT DOSE TOXICITY	7/31/17	BG, BW, CL, CO, DM, DS, EX, FW, LB, MA, MI, OM, PC, POOLDEF, PP, SE, SUPPMA, SUPPMI, TA, TE, TS, TX	6/10/22 11:27 AM	

# **SEND Data Loading Issues**




- Domains with duplicate USUBJIDs (in pooldef, pp Pharmacokinetic Parameters, fw – food and water consumption domains)
- TS (Trial Summary) or TX (Trial Sets) domains were not submitted
- Missing RFSTDTC (Reference Start date)



# Clinical Data: CBER Study Data standards validation Process

www.fda.gov

### **Study Data Validation Process**



www.fda.gov

#### **AE related issues**

• Inconsistency coding of the exact same term value

aeterm	aellt	aedecod	aehlt	aehlgt	aebodsys
ELEVATED BLOOD GLUCOSE	BLOOD GLUCOSE INCREASED	BLOOD GLUCOSE INCREASED	CARBOHYDRATE TOLERANCE ANALYSES (INCL DIABETES)	METABOLIC, NUTRITIONAL AND BLOOD GAS INVESTIGATIONS	INVESTIGATIONS
ELEVATED BLOOD GLUCOSE	HYPERGLYCEMIA	HYPERGLYCAEMIA	HYPERGLYCAEMIC CONDITIONS NEC	GLUCOSE METABOLISM DISORDERS (INCL DIABETES MELLITUS)	METABOLISM AND NUTRITION DISORDERS

#### **AE related issues:**

- No severity or toxicity grade populated
- SDTM AE that are not present in ADAE and vice versa
- Treatment emergent flag in SDTM is not consistent with ADaM treatment emergent flag
- ADAE.TRTEMFL not equal to Y, but ASTDT is within treatment period
- Serious adverse events are missing seriousness criteria
- AEOUT is inconsistent with AEENDTC

# FDA

#### **CE related Issues:**

- CESTDTC, CEENDTC, or CESTRTPT (ongoing not flagged) not provided for reactogenicity data
- Clinical Events have neither severity or toxicity grade provided
- Multiple rows for one event one subject (maybe due to different severity)
- CE duration determined inaccurately

### **DM related issues:**

- Subjects present in another domain but not found in DM domain
- Missing sex/race/country for treated subjects
- Missing important dates in DM

### **MH related issues:**

• Inconsistent value for MHDECOD



### LB related issues:

- Standard units missing
- Inconsistent unit values
- Missing Reference Range Upper/Lower Limit
- LBNRIND = NORMAL, but result is greater than normal range high



#### **Dates related issues:**

- Medical history events dates are after treatment start dates
- Records in different domains with dates happen after end of participation date in DM
- Events are missing start and end time-point

#### **Documentation (aCRF, define, reviewers' guide) related issues:**

- Incorrect file name, such as reviewers-guide.pdf or adifine.xml instead of csdrg.pdf or define.xml
- Documentation located in the wrong place
- No bookmarks or wrong bookmarks (SDTM Reviewer's Guide or Define.xml)
- No annotations in aCRF



#### **Documentation (aCRF, define, reviewers' guide) related issues:**

- Inconsistent version of MedDRA listed in Define.xml and SDTM Reviewer's Guide
- Variable listed as derived, but no computational method is provided
- Derivations reference variables in raw data, but raw data was not submitted



**Documentation (aCRF, define, reviewers' guide) related errors:** 

- Domain referenced in define.xml but dataset is missing
- ADaM datasets were submitted, but are not listed in the ADaM define.xml
- Define.xml for a different study
- No explanations of issues in reviewer's guide

#### **Other issues:**

- Inconsistent variable length
- Study subjects with missing baseline flags
- Data submitted in the wrong folder
- Missing values for one or more MedDRA variables
- Comments provided in other domains instead of CO

### Summary



- CBER is ready to support SEND data for non-clinical study submissions
- SEND is required for studies that start after March 15, 2023
- CBER validation process for clinical data, common issues should be avoided

### **Resources**



- Federal Register Notice regarding SEND for CBER
- FDA Data Standards Catalog
- <u>Study Data Technical Conformance Guide</u>
- FDA Study Data Standards Resources



# **Questions?**

*Email:* <u>cber-edata@fda.hhs.gov</u> for any questions regarding study data submissions to CBER